Title Page 1

- Title of the article: HPV self-sampling among long-term non-attenders to cervical cancer 2
- 3 screening in Norway: A pragmatic randomized controlled trial
- Author list: Gunvor Aasbø^{1,2}, Ameli Tropè³, Mari Nygård¹, Irene Kraus Christiansen⁴, 4
- Ingrid Baasland ^{3,5}, Grete Alrek Iversen⁶, Ane Cecilie Munk⁷, Marit Halonen Christiansen⁸, Gro Kummeneje Presthus⁴, Karina Undem^{1,9}, Tone Bjørge^{3, 10}, Philip E. Castle^{11,12} and Bo 5
- 6
- Terning Hansen^{1,13} 7

8 **Affiliations:**

- 9 ¹Department of Research, Cancer Registry of Norway, Oslo, Norway
- 10 ²Institute of Health and Society, University of Oslo, Oslo, Norway
- 11 ³ Cervical Cancer Screening Programme, Cancer Registry of Norway, Oslo, Norway
- ⁴National HPV Reference Laboratory, Department of Microbiology and Infection Control, Akershus University Hospital, 12 13 Lørenskog, Norway.
- 14 ⁵Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.
- 15 ⁶Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway
- 16 ⁷Department of Obstetrics and Gynaecology, Sørlandet Hospital Kristiansand, Kristiansand, Norway
- 17 ⁸Department of Obstetrics and Gynaecology, Stavanger University Hospital, Stavanger, Norway
- 18 ⁹ National Institute of Occupational Health, Oslo, Norway
- ¹⁰Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway 19
- 20 ¹¹Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
- 21 ¹²Divisions of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, 22 USA
- 23 ¹³Department of Infection Control and Vaccine, Norwegian Institute of Public Health, Oslo, Norway

- 25 Corresponding author: Gunvor Aasbø, PhD, Department of Research, Cancer Registry of
- 26 Norway, Oslo, Norway. Address: Postboks 5313 Majorstuen, 0304 Oslo, Norway
- gunvor.aasbo@medisin.uio.no, phone: +47 482 57 136 27

28	OrcID: 0000-0002-8981-5374
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	

1 Keywords: screening participation, cervical cancer, self-sampling, RCT, human

2 papillomavirus

3

4 Abstract:

Background: The main aim of the present study is to assess whether human papillomavirus
(HPV) self-sampling may increase cervical cancer screening participation among long-term
non-attenders in Norway.

8 Methods: A pragmatic randomized controlled trial was initiated in the national cervical

9 screening programme in March 2019. A random sample of 6000 women aged 35-69 years

10 who had not attended screening for at least 10 years were randomized 1:1:1 to receive either

11 (i) a reminder to attend regular screening (control arm), (ii) an offer to order a self-sampling

12 kit (opt-in arm), or (iii) a self-sampling kit unsolicited (opt-out arm).

Results: Total screening participation during 6 months following study invitation was 4.8%,

14 17.0% and 27.7% among women who received a standard reminder letter (controls), women

15 who could order a self-sample kit (opt-in) and women who received a self-sample kit

unsolicited (opt-out), respectively (P<0.0001). High-risk HPV was detected in 11.5% of the

self-samples and in 9.2% of the clinician-collected samples (P = 0.40). Most women (92.5%)

18 who returned a positive self-sample attended triage. Of 933 women screened in the study (by

a clinician or HPV self-sampling), 33 (3.5%) had CIN2+, 31 (3.3%) had CIN3+, and 11

(1.2%) had cervical cancer.

21 **Conclusion:** We conclude that opt-in and opt-out self-sampling increased screening

22 participation among long-term non-attenders.

23 Clinical Trial Registration: Clinical Trials.gov NCT03873376

1 Background

2 Screening has reduced cervical cancer incidence (1) and mortality (2) substantially in

3 Norway. However, coverage of the national cervical cancer screening programme has

4 stagnated at a suboptimal 70% (3), and cervical cancer incidence has increased by 14% from

5 the period 2009-2013 to 2014-2018 (3). Under- or unscreened women have an increased risk

6 of cervical cancer (4) and being diagnosed at an advanced stage (5). Thus, interventions that

7 improve screening participation would benefit women's health.

8 Approximately 17% of women aged 35-69 years in Norway have not been screened for at

9 least 10 years (3). In Sweden, the detection of high-grade cervical abnormalities among

10 women who had not been screened during the last 10 years was considerably higher than in

11 the general screening population (6), which highlights the need for improved interventions

12 among long-term non-attenders. Important reasons for non-attendance include procrastination,

13 embarrassment, fear of pain and previous negative experiences with the gynaecological exam

14 or a history of sexual abuse (6, 7), as well as practical barriers experienced in everyday life

15 (8). Non-attendance among Norwegian women is also associated with having a

16 male/foreign/young general practitioner (GP) (9), lacking awareness of the recommended

screening interval (10), and lower socioeconomic or migrant background (11). Self-sampling

18 for human papillomavirus (HPV) testing, which the women can perform themselves at home,

19 may reinforce the importance of screening, empower women, and mitigate some of the

20 barriers associated with attending a gynaecological screening exam.

21 HPV infection is a necessary cause of cervical cancer (12). A persistent infection with high-

risk HPV (hrHPV) may, through intermediate precancerous stages, lead to cancer (13).

23 Moreover, when cervical cancer is detected at a late stage, effective treatment is limited and

24 prognosis poor (14). When used with HPV assays based on polymerase chain reaction (PCR),

25 self-sampling and HPV testing identifies women with cervical precancer and cancer, cervical

intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+), with similar accuracy as

27 clinician-collected samples (15). Studies also show that self-sampling has a high acceptability

among women and is preferred over clinician sampling (16). Opt-out strategies, where women

29 receive a self-sampling kit unsolicited, proved to increase screening participation of under-

30 screened women in a relatively recent meta-analysis (15), and in Norway (17). Opt-in

31 strategies, where women must request a self-sampling kit, have generally not been found to be

32 more effective than invitation letters for increasing screening participation. The effect of self-

sampling on participation varies between studies, especially for opt-in strategies, and warrant
 more studies (15).

Studies on the effect of HPV self-sampling on participation among under-screened women often include women only slightly overdue for screening, who may be easier to engage than long-term non-attenders, while few randomized controlled trials have by design specifically targeted long-term non-attenders (6, 18-21). It is important to gain more knowledge on how secondary cancer prevention among long-term non-attenders may be improved because they may be at a relatively high risk for CIN2+.

9 *Aim*

The primary aim of this study was to compare cervical cancer screening participation among women in Norway who have not attended screening for at least 10 years, who received either a standard reminder letter to attend screening in a clinic (control arm), an offer to order an HPV self-sampling kit (opt-in arm), or were sent an unsolicited HPV self-sampling kit (optout arm). As secondary endpoints, we estimated hrHPV positivity rates, attendance to triage after an HPV positive self-sample, and occurrence of CIN2+ among the long-term nonattenders who participated in screening.

17

18 Materials and Methods

19 *Cervical screening in Norway*

20 The Cancer Registry of Norway (CRN) is responsible for the national cervical cancer 21 screening programme (NCCSP), and invites women aged 25 to 69 years to attend screening. 22 The programme is currently transitioning from cytology every three years to HPV primary 23 screening every five years for women aged 34-69 years. NCCSP uses a centralised invitation 24 procedure and issues standard open reminder letters to women who have not been registered 25 with a screening test during the recommended interval. A second reminder is issued after one 26 year if a woman is still not registered with a test result. These reminders encourage women to 27 schedule an appointment with their GP for a screening test. All cytology and HPV screening 28 results, as well as any associated histology results, are registered in the NCCSP database. All 29 records are associated with the personal identity number unique to each Norwegian resident.

30 Study population and design

The target population was women residing in the counties of Hordaland, Rogaland, Sør-1 2 Trøndelag and Vest-Agder who had not participated in the screening programme for the last 3 10 years. These regions consist of mixed rural and urban areas and cover about one-third of 4 the Norwegian population. During the study, primary screening was offered by HPV-test in 5 Hordaland, Rogaland and Sør-Trøndelag, and by cytology in Vest-Agder. A priori power 6 calculations showed that we needed at least 1417 women in each intervention arm to detect a 7 difference of 5 percentage points between the control arm and the intervention arms with 90% 8 power. Using the NCCSP database, we identified 28,125 women who were eligible for the 9 study, of which 6000 (21.3%) were randomly selected for invitation to the study. The 10 randomly selected women were individually randomized 1:1:1 into the control, opt-in or opt-11 out intervention arm without further restrictions. The eligible women were unaware of the 12 randomization. Blinding was not possible due to the nature of the interventions. 13 Randomization procedures were performed using the sample function in Stata by a 14 programmer who was not involved in the conduct of the trial. Invitations were sent during 15 March-August 2019.

- 16 A total of 333 (5.6%) invited women, similarly distributed by intervention arm; 108 (5.4%) in
- the control arm, 103 (5.1%) in opt-in arm, and 122 (6.1%) in opt-out arm; P = 0.4), were
- 18 excluded from the study due to: (i) incorrect address, (ii) active refusal to participate in the
- 19 study, or (iii) ineligibility for the study (living abroad/had prior hysterectomy/had a screening
- 20 test between study sampling and invitation) (see Figure 1). The trial was registered at
- 21 ClinicalTrials.gov on 8 March 2019 (NCT03873376).

22 Invitation letters and information

23 Women in the control arm received a NCCSP reminder letter to attend regular screening (i.e.,

- encouraging the women to schedule an appointment with their GP). The letter also stated that
- they were randomly selected to participate in a study aiming to improve cervical cancer
- 26 prevention. The letter included no information about self-sampling.

27 Women in the opt-in arm received an invitation letter to order a self-sampling kit. The women

- could order by mail, e-mail, or through a webpage. The invitation included a unique order
- 29 code, information about the study, a reply slip, and a pre-paid envelope to return the order. A
- 30 dedicated webpage for ordering a self-sampling kit was available in Norwegian, English,
- 31 French, Spanish, Polish, Turkish and Arabic. Each order code could only generate one web
- 32 order.

A self-sampling kit was mailed unsolicited to women in the opt-out arm, together with the
study invitation letter. The content in the opt-in and opt-out invitation letters was the same
(apart from the description of the ordering procedure in the opt-in letter) and included
information that the women alternatively could schedule a regular screening appointment with
their GP if they did not want to use the self-sample.

6 Similar to regular NCCSP reminders, all invitation letters contained general screening 7 information. The letters were on NCCSP stationary and were signed by the NCCSP head. In 8 addition, letters contained study-specific information, a link to the study webpage, and 9 information that they could refrain from participating in the study. All invitation letters were 10 in Norwegian, except for an English reference to a webpage. The study webpage was 11 available in Norwegian and English and included a link to an instructional video on how to 12 collect a self-sample with options for Norwegian or English audio, and English, French, 13 Spanish, Polish, Turkish or Arabic subtitles.

14 The HPV self-sampling kit

15 The kit included the self-sampling device with user instructions, a sealable plastic bag, a 16 prepaid return envelope addressed to the laboratory, and an information leaflet. The Evalyn® 17 Brush (dry brush) (Rovers Medical Devices B.V, Oss, Netherlands) was used for self-18 sampling in this study. The self-sampling device had a hidden radio frequency identification 19 chip containing a pseudonymized number unique to each invited woman and had no visible 20 personal information. Women returned the self-sample in the plastic bag and mailed it in the 21 return envelope. Women who had not ordered/returned a self-sample within three weeks 22 received one reminder letter to order/return the self-sample. The self-sampling kit was free of 23 charge for the women.

24 HPV detection from self-sampled screening test

25 All self-samples were analysed at the Norwegian HPV reference laboratory at Akershus 26 University Hospital. Soon after receipt at the laboratory, the brush tip was removed from the 27 self-sampling device, transferred to a vial with 4.5 mL ThinPrep PreservCyt and stored at 28 room temperature for at least 24 hours. During storage, tubes with the brush tip were vortexed 29 three times for 15 seconds to ensure proper dissolution of the sample material. The samples 30 were tested for hrHPV using the cobas® 4800 HPV test (Roche Molecular Systems, Inc, 31 Branchburg, NJ), which individually reports HPV16 and HPV18, in addition to a pooled 32 result of the 12 hrHPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Beta-globin is

included as internal quality control in a fourth channel. Samples with an invalid test result at
 first run were retested, which gave a valid test result in every case. Analysis was completed
 within 21 days after receipt for all samples.

4 *Clinical management*

5 All women who returned a self-sample were informed about their test result per ordinary mail 6 within six weeks after receipt of the self-sample in the lab. Women with an HPV negative 7 result were encouraged to continue attending the regular cervical cancer screening programme 8 at the recommended interval. Women with a hrHPV positive self-sample received the result 9 together with a pre-booked triage appointment with a physician. To address feasibility and 10 performance of alternative triage strategies that could be implemented in a screening programme, women were sequentially allocated to triage at their GP or a gynaecologist 11 12 practicing in the largest city in their county. The notification letter to women in each group 13 was identical. Physicians were informed that the patient had tested positive for HPV after 14 participating in a study offering HPV self-sampling to long-term non-attenders. Women 15 referred to GP triage underwent cytology, while women referred to gynaecologist triage 16 underwent further gynaecological examination, which always included cytology and 17 colposcopy, and biopsy if deemed necessary. To simulate a routine healthcare setting, the 18 women paid the deductible for the GP or the gynaecologist appointment themselves (about 19 30€ and 60€ respectively), as they would in the NCCSP. Management after the scheduled 20 triage visit of women who had a positive hrHPV self-sample was not specific for the study 21 and thus follow national guidelines (22). Similarly, women who had a clinician-collected 22 screening sample (irrespective of treatment arm), or who had a triage cytology with another 23 physician than she was allocated to in the study were managed outside the study. According 24 to the national screening algorithm, women who are HPV16/18 positive are referred to 25 colposcopy with biopsy if the cytology is low- or high-grade, or to a new HPV-test in 12 26 months if the cytology is normal. Women who are positive for other hrHPV-types are referred 27 to colposcopy with biopsy if cytology high-grade, to a new HPV-test in 12 months if cytology 28 low-grade, or to a new HPV-test in 24 months if cytology normal. Cytology is reported 29 according to the Bethesda system.

30 Registry data collection

Data regarding clinician-collected screening tests (including triage tests taken outside the
 study) was taken from the NCCSP database. Data on histological outcomes from colposcopy

1 referrals were taken from the NCCSP and the CRN databases. Dates were delivered by month

2 and year. If several histological diagnoses were available for the same women, we only

3 considered the most severe diagnosis. The last registry linkage was performed in December

4 2020, which allowed at least 16 months of registry follow-up after study invitation. Histology

5 diagnoses were interpreted according to WHO guidelines (23). Income data was collected by

6 linkage to Statistics Norway.

7 Statistical analysis

8 Screening participation was defined as returning a valid self-sample or having a clinician-9 collected screening test within six months after receipt of the invitation letter. Attendance to 10 triage was assessed among women with a hrHPV positive self-sample and was defined as attending at the allocated physician (i.e., GP or study gynaecologist) or an unallocated 11 12 physician within six months of notification of a positive self-sample. Women who returned a 13 hrHPV positive self-sample and who were not registered with a cytology test by three months 14 following the scheduled appointment, received a reminder from the NCCSP encouraging 15 them to order an appointment at their GP.

We present numbers and proportions of screening participation by intervention arm 16 17 (control, opt-in, opt-out) overall, by age groups (36-45, 46-55, 56-65, 66-69) and by screening 18 history (time since last screening test 10-15 years, 16-28 years, never). For each self-sampling 19 arm, we present total participation as well as clinician-sampled and self-sampled participation 20 separately. Controls were only screened by a clinician. Differences in screening participation 21 among intervention arms are presented for total participation (i.e., intention to treat), as 22 absolute participation differences (APD, percentage points) and as relative participation 23 differences (RPD, relative risks) with associated 95% confidence intervals (95% CI). Further, 24 we present numbers and proportions of hrHPV positive screening tests and histologically 25 verified high-grade lesions by intervention arm. To investigate the diagnostic yield by mode 26 of triage, we also present the histologically verified high grade lesions separately for women 27 triaged by study gynaecologists, women triaged by study GPs, and women who had a 28 clinician-collected screening test or attended triage outside the study (i.e., women not 29 managed by a study gynaecologist/GP). Since women who have a clinician-collected 30 screening test do not need a separate triage visit, attendance to triage is only presented for 31 women who tested positive by self-sampling. We present attendance to triage by self-32 sampling arm and by mode of triage (i.e., at gynaecologist or GP). For comparisons of counts 33 and proportions, P-values refer to chi-squared tests, or the Fisher's exact test for observed

- 1 counts <5. For comparisons of central tendency, P-values refer to the Mann-Whitney U-test.
- 2 All tests were two-sided and P-values <0.05 were considered statistically significant.
- 3 Analyses were performed using Stata version 17MP or R version 3.5.3.
- 4

5 **Results**

6 All baseline characteristics addressed in the study cohort were similarly distributed by study

7 arm (Table 1). The mean age was 54.5, 54.4 and 54.1 years among women in the control, opt-

8 in and opt-out arm. Similar frequency distributions in each study arm were observed for

9 categories of age (P=0.94), time since last screen (P=0.99), county of residence (P=0.96) and

10 income (P=0.28) (Table 1).

11 Total participation (i.e., self-sampled and clinician-sampled tests for the self-sampling arms)

12 was 4.8% in the control arm, 17.0% in opt-in arm and 27.7% in opt-out arm (P < 0.0001,

13 Figure 2, Table 2). Thus, absolute participation differences and relative participation

14 differences in total participation was: 12.3% (95% CI 10.3 - 14.2) and 3.6 (95% CI 2.9 - 4.5),

15 respectively for opt-in vs. controls; 22.9% (95% CI 20.7 - 25.2) and 5.8 (95% CI 4.7 - 7.2),

16 respectively, for opt-out vs. controls; and 10.7% (95% CI 8.0 - 13.3) and 1.6 (95% CI 1.4 -

17 1.8), respectively, for opt-out vs. opt-in. Differences in participation between intervention

18 arms were largely due to self-sampling use, since there was similar attendance to clinician-

19 collected screening: 4.8% for the control arm, 3.8% for opt-in, and 4.0% for opt-out (P = 0.33,

20 Table 2).

In the opt-in arm, 403 out of 1897 (21.2%) women ordered a self-sample, of which 144

- 22 (35.7%) ordered after receiving a reminder, and 250 (13.2%) returned the self-sample for
- analysis. Opt-in orders were made by ordinary mail (51.6%), web (33.0%), e-mail (14.2%) or

telephone to the study centre (1.2%; not presented as an option in the invitation letter).

Among 445 women in the opt-out arm who submitted a self-sample, 254 (57.1%) did so after receiving a reminder.

27 Self-sampling increased total participation in all age groups and screening history categories.

28 Total participation was consistently highest in the opt-out arm, intermediate in the opt-in arm

and lowest in the control arm (Table 2). In each arm, total participation was highest in the

30 youngest age group (age 36-45 years), at 8.0%, 18.5% and 32.9% among controls, opt-in and

31 opt-out, respectively, and tended to decrease with age (P-trend in total participation by age

group: 0.001, 0.15 and 0.002 for controls, opt-in and opt-out, respectively). Participation 1 2 generally decreased with increasing time since last screening test, and this pattern was evident for both clinician-sampling and self-sampling, and in each intervention arm (P-trend in total 3 4 participation by time since last screening test (10-15 years, 16-28 years or never screened): 5 <0.0001, <0.0001 and 0.004 for controls, opt-in and opt-out, respectively). Among women 6 who never had been screened previously, total participation was 1.9% for controls, 11.4% for 7 opt-in and 25.0% for opt-out (P < 0.0001). Also, the RPD was highest among never screeners, 8 at 6.1 (95% CI 3.4 - 11.1), 13.4 (95% CI 7.5 - 23.8) and 2.2 (95% CI 1.7 - 2.8) for opt-in vs. controls, opt-out vs. controls and opt-out vs. opt-in, respectively (Table 2). 9 10 Among all women who were tested for HPV, 11.0% were positive for any hrHPV. The hrHPV positivity rate was slightly higher for self-sampled tests than for clinician-collected 11 12 tests, at 11.5% and 9.2% respectively (P = 0.40, Table 3). Among controls, 6.0% were 13 positive for any hrHPV, which was non-significantly lower than observed among women in the opt-in (10.8%) and opt-out (11.8%) intervention arms (P = 0.28) (Table 3). 14 15 Triage attendance was similar in the opt-in and opt-out arms, at 77.8% and 79.3% (P = 1), 16 respectively, for scheduled attendance, and 92.6% and 92.5% (P = 1), respectively, for any 17 attendance within six months (Table 4). Attendance for women allocated to gynaecologist 18 triage (irrespective of intervention arm) for scheduled and any attendance was 75.6% and 19 90.2%, respectively, which was non-significantly lower than observed among women 20 allocated to GP triage, who had corresponding attendance of 82.1% and 94.9% (P = 0.67 for 21 scheduled attendance, P = 0.72 for any attendance, Table 4). The median (interquartile range 22 (IQR)) period between a positive self-sample and the scheduled triage appointment was 23 shorter for women allocated to GP triage than gynaecologist triage, at 19 (IQR 14, 25) and 43 24 (IQR 29, 54) days (P < 0.0001), respectively. However, among women who were biopsied 25 and had a histology result, the median (IQR) period between the positive self-sample and the 26 histological diagnosis was longer for women who were allocated to and attended GP triage 27 than for women who were allocated to and attended gynaecologist triage, at 4 (IQR 3, 8) and 3 (IQR 2, 3) months, respectively (P = 0.01). 28

A total of 1, 12, and 20 prevalent cases of CIN2+ were detected in the control, opt-in, and opt-out arms, respectively (Table 5). Thus, we detected CIN2+ in 0.1%, 0.6% and 1.1% of the invited women (P = 0.0002), and in 1.1%, 3.7% and 3.8% of the screened women (P = 0.52)

32 in the control, opt-in, and opt-out arms, respectively. A total of 0, 4 and 7 cases of cervical

33 cancer were detected in the control, opt-in and opt-out arms, respectively, giving

corresponding detection rates per woman screened of 0%, 1.2% and 1.3% (P = 0.81). In each
of the self-sampling arms, the detection rate of CIN2+ and cancer per woman screened was
similar among women who screened by self-sampling and women who attended screening at
a clinic (Table 5).

5 A relatively high proportion of women with screening-positive tests were subsequently 6 diagnosed with CIN2+ (Table 6). Although the percentage of histologic diagnoses was higher 7 in the group attending gynaecologist triage, the CIN2+ yield was similar in this group when 8 compared to women attending GP triage and women who were screened in a clinic or were 9 triaged outside the study, at 32.3%, 34.4% and 35.3% of the screening-positive tests, 10 respectively. Similar occurrence was observed for CIN3+, thus few of the histologically verified cases were CIN2, an equivocal diagnosis of precancer (24). Cancer was diagnosed in 11 12 four women who attended gynaecologist triage, four women who attended GP triage, and 13 three women who attended screening at a clinic or triage outside the study, which constituted 14 12.9%, 12.5% and 8.8% of the screening-positive tests respectively. For all screening and 15 triage modes, the CIN2+ yield was considerably higher among women who tested positive for 16 HPV16/18 than among women who were positive for other hrHPV types. Among women 17 who screened positive for HPV16/18, the percentage of CIN2+ was 64.3%, 55.6% and 69.2% 18 for women attending gynaecologist triage, GP triage, and women who attended screening at a 19 clinic or triage outside the study, respectively (Table 6).

20 Discussion

We show that offering HPV self-sampling to long-term non-attending women as opt-in or as opt-out significantly increases the cervical screening participation relative to the standard reminder letter, and that opt-out gives the largest increase in participation.

24 Although the effect of self-sampling interventions may differ between studies due to 25 differences in study design and screening setting, increased participation by the opt-out self-26 sampling strategy is well established compared to clinician-collected screening (15, 25). In 27 the present study, we observed larger absolute and relative differences in participation 28 between the opt-out self-sampling arm and the controls than was reported in a recent meta-29 analysis of self-sampling (15). Moreover, we observed significantly increased participation 30 for the opt-in strategy, which was not found in the meta-analysis (15). Our results regarding 31 self-sampling participation generally coincide with randomized controlled trials that have

targeted long-term non-attenders (6, 18-20) or show stratified analyses for this part of the
 screening population (21, 26).

3 Characteristics of the targeted screening population are important for the way in which self-sampling interventions may affect participation. When self-sampling is offered more 4 widely to women who are overdue for screening, it tends to replace screening at a clinic in 5 6 addition to increase overall participation (17, 21). We observed that the clinician-collected 7 screening uptake was only marginally lower in the self-sampling arms than in the control arm, 8 indicating that self-sampling hardly replaces clinician-collected screening when offered 9 exclusively to long-term non-attenders. Our observation that some long-term non-attending 10 women offered self-sampling still preferred to be screened by a clinician, demonstrates the 11 importance of maintaining this option even if self-sampling is implemented in the Norwegian 12 screening programme. Overall, we report similar effects on participation as a Swedish study 13 targeting long-term non-attenders (6). However, the absolute increases in participation for the 14 self-sampling interventions versus controls were considerably higher in our study, but the 15 relative participation difference was lower, which may relate to the slightly different 16 screening contexts experienced by long-term non-attending women in these countries. For 17 instance, the Swedish screening programme issues far more screening reminders than the 18 Norwegian programme and offers prescheduled screening appointments rather than an 19 encouragement to order an appointment for screening, which in part may explain the higher 20 coverage observed for ordinary screening in Sweden (4) and the very low participation to 21 clinician-collected screening among long-term non-attenders (6). On a general note, groups 22 that respond poorly to the control intervention, i.e. the standard invitation to attend screening 23 in a clinic, have a high potential to benefit from self-sampling in relative terms, as we can 24 observe in the relative participation difference estimates of the never-screeners and the 25 women in the oldest age brackets in our study population.

26 Although inferior to opt-out, we found that opt-in also increased screening 27 participation when compared to controls who received the routine reminder letter. Thus, this 28 type of intervention should not be dismissed, although opt-in in other settings often did not 29 improve participation beyond a routine reminder letter to screen (15). The way in which this 30 intervention is offered may be of particular importance for achieving increased participation. 31 The present study results suggest that alternative ordering options that include ordinary mail 32 and a web-solution may be considered for opt-in among long-term non-attenders, and that a 33 reminder to order the self-sampling device may be effective. Some effect of opt-in has also

been reported in intention-to-treat analyses of other randomized controlled trials (6, 21) and
 observational studies (27, 28) in Scandinavia.

3 Long-term non-attending women may be hesitant to undergo a gynaecological 4 examination for screening purposes (29), but our study showed that the vast majority attended 5 to examination by a physician if they submitted a positive self-sample. The attendance to 6 triage observed among women with a positive hrHPV self-sample was somewhat higher than 7 attendance to follow-up after positive screening tests in the NCCSP (3). A high attendance to 8 triage after a positive self-sample has also been found in other settings (15). We found that 9 triage attendance was similar for women who were scheduled for GP and gynaecologist 10 triage. However, some women chose to be triaged by another physician than they were allocated to in the study, and this happened slightly more often among women allocated to a 11 12 gynaecologist than among women allocated to their GP. One reason for this difference could 13 be that the gynaecologists on average were located further away from the women than their 14 GP. Moreover, we observed a longer time lag between notification and the scheduled 15 appointment for women allocated to a gynaecologist, which could have compelled more of 16 these women to reschedule to a physician who could offer an earlier appointment.

The hrHPV positivity rate of the total study population of long-term non-attenders was nearly twice as high as the corresponding rate among women of the same age in the ordinary screening population (3). In both self-sampling arms, women who chose to attend screening at a clinic and women who chose to use self-sampling had similar hrHPV positivity rates, indicating that the mode of screening chosen by long-term non-attending women is not associated with risk of infection.

23 Due to low numbers, the CIN2+ occurrence observed here should be interpreted with 24 caution, especially in terms of comparisons between intervention arms or other subgroups. 25 Among all the long-term non-attending women who were screened during the study, 3.5% 26 and 1.2% were diagnosed with CIN2+ and cervical cancer, respectively, while the 27 corresponding rate among women aged 34-69 years in the NCCSP is 1.2% and 0.1% (3). 28 Thus, CIN2+ and cervical cancer yield among long-term non-attenders observed in this study 29 was very high compared to the ordinary screening population, which probably reflects a real 30 difference in risk. However, surveillance bias could also have contributed since most 31 physicians who triaged women who had submitted a hrHPV-positive self-sample knew that 32 they were long-term non-attenders and part of a study, and women who were triaged by a 33 study gynaecologist underwent colposcopy at the triage visit. However, the occurrence of

CIN2+ among women with a positive screening test (hrHPV or cytology) was very similar
 regardless of differences in diagnostic follow-up.

3 GP and gynaecologist triage of long-term non-attending women who had a hrHPVpositive self-sample gave similar attendance and diagnostic yield. However, for long-term 4 non-attending women who have CIN2+, it is important to be treated quickly, and our results 5 6 clearly showed that the final diagnostics appeared earlier if women were referred directly to a 7 gynaecologist who could perform a colposcopic biopsy at the triage visit than if they were 8 referred to their GP for cytology triage. Furthermore, the CIN2+ and CIN3+ detection rates 9 among long-term non-attenders with a positive screening test exceeded the risk thresholds for 10 which colposcopy usually is considered good practice (30, 31).

11 Strengths and limitations

12 A strength of the present study is the use of national registry data that ensures a precise 13 definition of the study cohort and complete information on participation and diagnostics. Targeted sampling of long-term non-attenders also ensures a sufficient sample size for robust 14 15 inference regarding comparisons of participation by study arm in this part of the screening 16 population. Another strength is the randomized design that enhances the representativeness of 17 the study sample and the similarity of the intervention arms. The intervention arms should 18 thus be highly comparable, and the results of the present study should have high 19 generalizability to the population of long-term non-attenders in Norway. Furthermore, we 20 used a self-sampling device and a PCR-based HPV DNA test that were clinically validated 21 and gave no invalid self-samples in this study. Finally, the trial was embedded in the NCCSP, 22 which should make the study results relevant to a real-world scenario where self-sampling is 23 offered as part of an organized programme. However, the invited women were informed that 24 this was a study, which could have influenced their motivation to participate. A further 25 limitation is the relatively low subgroup numbers regarding hrHPV positivity, attendance to 26 triage and CIN2+ occurrence, which limits the precision of the inference that can be made 27 regarding these secondary outcomes of the study.

28

29 Conclusion

We conclude that opt-in and opt-out self-sampling strategies increase screening participation
among long-term non-attenders to cervical screening in Norway. If implemented as part of the

screening programme, both strategies would probably improve secondary prevention of 1 2 cervical cancer and thus benefit women's health. Long-term non-attenders also have an elevated risk for hrHPV infection and high-grade cervical lesions, which highlights the large 3 4 potential to improve cervical cancer prevention by increasing the screening participation of 5 this population. The opt-out strategy would maximize the preventive effect because it clearly 6 increased participation the most. Maintaining an offer for clinician-collected screening will 7 still be important, since some long-term non-attenders offered self-sampling preferred this 8 option. We also show that management of hrHPV-positive self-samples by GP cytology triage 9 or direct referral to colposcopy by gynaecology specialists give similar results in terms of 10 triage attendance and diagnostic yield. Our study supports findings that direct referral to 11 colposcopy might be the best option for hrHPV-positive women in this population, especially if they are positive for HPV16/18, because they are at a relatively high risk for sequelae and 12 13 colposcopy referral gives the shortest lag to a histologically confirmed diagnosis and 14 treatment. Colposcopy is generally a safe procedure, thus over-referral will not be a burden 15 for the patient.

16

17 Additional Information

<u>Acknowledgements:</u> We thank Mona Hansen for valuable contribution in the planning and
preparation of procedures for sample and data handling at the laboratory; Suzanne Campbell
and Kristina S. Gjøtterud for data management; Kristin H. Brenden, Gintaras Pikelis, Håkan
Olofsson, Caroline Skudal and Björn Eklund for IT design and support; Randi Waage and Gry
B. Skare for NCCSP support; Pia C.M. Osborne and Minh T. Le for data collection
assistance, and Jeanette Hoel who was the user representative of the study.

24 <u>Authors' contributions:</u> BTH, MN and AT conceived the study. GA, IKC, TB and PEC

contributed to the study design. BTH was the principal investigator. BTH, GA and KU

coordinated the execution of the trial. IKC supervised sample flow and HPV-testing. BTH and

27 GA were responsible for data analyses. IB, GAI, ACM, MHC and GKP contributed to data

collection. GA wrote the first manuscript draft with support from BTH. All authors

29 commented on drafts and approved the final manuscript.

30 <u>Ethics approval and consent to participate:</u> The South-Eastern Committee A for Medical and

Health Research Ethics in Norway approved the study (project-ID: 2019/111) and Oslo

32 University Hospital Data Protection Officer approved the processing of data in the study

(project-ID: 18/14056). In addition, a statement regarding the processing of personal data was 1 2 also obtained from the Data Protection Officer at Akershus University Hospital. For women in self-sampling arms, the invitation included information that by returning the self-sample, 3 4 they consented to the subsequent procedures described in the invitation letter. All invited 5 women, including those in the control arm, were informed that they could withdraw from the 6 study at any time. The study was performed in accordance with the Declaration of Helsinki 7 Consent for publication: Not applicable 8 Data availability statement: The data contains personal information and the study participants 9 have not consented to public data sharing. Data access requires permission by relevant 10 Norwegian authorities. 11 Competing Interests: Dr. Castle has received HPV tests and assays for research at a reduced 12 or no cost from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. All other 13 authors declare no conflict of interest. 14 Funding information: This study was funded by the Norwegian Cancer Society and Thea 15 Steen Memorial fund (grant number 182687-2016). The funding source had no role in study 16 design, data collection and analysis, preparation of the manuscript, or decision to publish. 17 Disclaimer: The opinions expressed by the authors are their own and this material should not 18 be interpreted as representing the official viewpoint of the U.S. Department of Health and 19 Human Services, the National Institutes of Health, or the National Cancer Institute. 20

21 **References**

Lönnberg S, Hansen BT, Haldorsen T, Campbell S, Schee K, Nygård M. Cervical
 cancer prevented by screening: Long-term incidence trends by morphology in Norway. Int. J.
 Cancer 2015;137, 7: 1758-64.

Haldorsen T, Skare GB, Steen R, Thoresen SO. Livmorhalskreft etter ti års offentlig
 koordinert screening. [Cervical cancer after 10 years of nationally coordinated screening].
 Tidskr. Nor. Legefor. [Journal of the Norwegian Medical Association.] 2008;128, 6: 682-85.
 Cancer Registry of Norway. Annual rapport 2019, Screening Activity and Results
 from the National Cervical Cancer Screening Programme, [Årsrapport 2019,

30 Screeningaktivitet og resultater fra Livmorhalsprogrammet]. 2020. Available:

https://www.kreftregisteret.no/globalassets/livmorhalsprogrammet/rapporter/arsrapport-1 lp/arsrapport-livmorhalsprogrammet-2019v2_sept2021.pdf [Accessed 10 Febr. 2022]. 2 4. Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et. al. Screening-3 4 preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer 5 Inst 2008;100, 9: 622-9. 5. 6 Pedersen K, Burger EA, Campbell S, Nygård M, Aas E, Lönnberg S. Advancing the 7 evaluation of cervical cancer screening: development and application of a longitudinal 8 adherence metric. Eur. J. Public Health 2017;27, 6: 1089-94. 9 6. Elfström KM, Sundström K, Andersson S, Bzhalava Z, Carlsten Thor A, et al. 10 Increasing participation in cervical screening by targeting long-term nonattenders: 11 Randomized health services study. Int. J. Cancer 2019;145, 11: 3033-9. 12 7. Cadman L, Waller J, Ashdown-Barr L, Szarewski A. Barriers to cervical screening in 13 women who have experienced sexual abuse: an exploratory study. J Fam Plan Reprod Health 14 Care 2012;38, 4:214-20. 15 8. Chorley AJ, Marlow LAV, Forster AS, Haddrell JB, Waller J. Experiences of cervical 16 screening and barriers to participation in the context of an organised programme: a systematic 17 review and thematic synthesis. Psycho-Oncol 2017;26, 2:161-72. 18 9. Leinonen MK, Campbell S, Klungsøyr O, Lönnberg S, Hansen BT, Nygård M. 19 Personal and provider level factors influence participation to cervical cancer screening: A 20 retrospective register-based study of 1.3 million women in Norway. Prev. Med 2017;94:31-9. 21 10. Hansen BT, Hukkelberg SS, Haldorsen T, Eriksen T, Skare GB, Nygard M. Factors 22 associated with non-attendance, opportunistic attendance and reminded attendance to cervical 23 screening in an organized screening program: a cross-sectional study of 12,058 Norwegian 24 women. BMC Public Health 2011;11:264. 25 11. Leinonen MK, Campbell S, Ursin G, Trope A, Nygard M. Barriers to cervical cancer 26 screening faced by immigrants: a registry-based study of 1.4 million women in Norway. Eur. 27 J. Public Health 2017;27, 5:873-9. 28 12. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. 29 Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol 30 1999;189,1:12-9. 31 13. Egawa N, Egawa K, Griffin H, Doorbar J. Human Papillomaviruses; Epithelial 32 Tropisms, and the Development of Neoplasia. Viruses 2015;7,7:3863-90. 33 14. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet 34 2019;393,10167:169-82.

Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and
 reaching underscreened women by using HPV testing on self samples: updated meta-analyses.
 BMJ 2018;363:k4823.

16. Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of
self-sampled screening for HPV DNA: a systematic review and meta-analysis. Sex Transm
Infect 2017;93,1:56-61.

Final France F

18. Broberg G, Gyrd-Hansen D, Miao Jonasson J, Ryd ML, Holtenman M, Milsom I, et
al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term
non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int. J. Cancer
2014;134, 9:2223-30.

14 19. Sultana F, English DR, Simpson JA, Drennan KT, Mullins R, Brotherton JM, et al.

15 Home-based HPV self-sampling improves participation by never-screened and under-

screened women: Results from a large randomized trial (iPap) in Australia. Int. J. Cancer.
2016;139,2:281-90.

20. Kellen E, Benoy I, Vanden Broeck D, Martens P, Bogers JP, Haelens A, et al. A
randomized, controlled trial of two strategies of offering the home-based HPV self-sampling
test to non- participants in the Flemish cervical cancer screening program. Int. J. Cancer
2018;143,4:861-8.

Tranberg M, Bech BH, Blaakaer J, Jensen JS, Svanholm H, Andersen B. Preventing
 cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening

participation more than timely opt-in procedures - a randomized controlled trial. BMC Cancer
2018;18,1:273.

26 22. Norwegian Directorate of Health. National Guidelines of Gynaecological Cancer

27 [Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft]. 3. ed. 2021.

28 Available: https://www.helsedirektoratet.no/retningslinjer/gynekologisk-kreft-

29 handlingsprogram [Accessed 08. Febr. 2022].

30 23. Tavassoli FA, Devilee P. eds. Pathology and Genetics of Tumours of the Breast and

31 Female Genital Organs. WHO Classification of Tumours, 3rd ed. Vol. 4. Lyon: IARC Press;

32 2003.

1 24. Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Hernándes JC, Glazer-Livson S, 2 et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active 3 surveillance: systematic review and meta-analysis. BMJ 2018;360: k499. 4 25. Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJ, Arbyn M. Reaching 5 women who do not participate in the regular cervical cancer screening programme by offering 6 self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur. J. Cancer 7 2015;51,16:2375-85. 8 26. Cadman L, Wilkes S, Mansour D, Austin J, Ashdown-Barr L, Edwards R, et al. A 9 randomized controlled trial in non-responders from Newcastle upon Tyne invited to return a 10 self-sample for Human Papillomavirus testing versus repeat invitation for cervical screening. 11 J Med Screen 2015;22,1:28-37. 12 27. Lam JU, Rebolj M, Moller Ejegod D, Pedersen H, Rygaard C, Lynge E, et al. Human 13 papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with 14 electronic communication platforms. Int. J. Cancer 2017;140,10:2212-9. 15 28. Sanner K, Wikström I, Strand A, Lindell M, Wilander E. Self-sampling of the vaginal 16 fluid at home combined with high-risk HPV testing. Br. J. Cancer 2009;101,5:871-4 17 29. Aasbø G, Solbrække KN, Waller J, Tropé A, Nygård M, Hansen BT. Perspectives of 18 non-attenders for cervical cancer screening in Norway: a qualitative focus group study. BMJ 19 Open 2019;9,8:e029505. 20 30. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide 21 the prevention of cervical cancer. Am J Obstet Gynecol 2007;197,4:356.e1-.e3566. 22 31. Arbyn M, Roelens J, Martin-Hirsch P, Leeson S, Wentzensen N. Use of HC2 to triage 23 women with borderline and mild dyskaryosis in the UK. Br. J. Cancer 2011;105,7:877-80. 24 25

- 26
- 27

Characteristic	Total, r	Total, all arms <i>n</i> (%)		rol group n (%)	C)pt-in n (%)	Opt-out n (%)		
Total invited	5,667	(100)	1,892	(100)	1,897	(100)	1,878	(100)	
Age (years)									
36 to 45	1,318	(23.3)	435	(23.0)	433	(22.8)	450	(24.0)	
46 to 55	1,520	(26.8)	497	(26.3)	520	(27.4)	504	(26.8)	
56 to 65	1,961	(34.6)	663	(35.0)	653	(34.4)	646	(34.4)	
66 to 69	868	(15.3)	298	(15.7)	292	(15.4)	278	(14.8)	
Mean age (standard deviation)	54.3	(9.9)	54.5	(10.0)	54.4	(9.8)	54.1	(9.9)	
Time since last screening test									
10 - 15 years	1,786	(31.5)	599	(31.7)	590	(31.1)	599	(31.9)	
Over 15 years	1,950	(34.4)	650	(34.3)	658	(34.7)	642	(34.2)	
Never screened	1,931	(34.1)	644	(34.0)	650	(34.2)	637	(33.9)	
County									
Hordaland	2,106	(37.1)	707	(37.3)	710	(37.4)	689	(36.7)	
Rogaland	1,705	(30.1)	568	(30.0)	563	(29.7)	574	(30.6)	
Trøndelag	1,217	(21.5)	415	(21.9)	405	(21.3)	399	(21.2)	
Vest-Agder	639	(11.3)	203	(10.7)	220	(11.6)	216	(11.5)	
Total income (tertiles) ¹									
Low	1,877	(33.3)	622	(33.0)	632	(33.5)	623	(33.4)	
Medium	1,878	(33.3)	610	(32.4)	659	(34.9)	609	(32.7)	
High	1,877	(33.3)	650	(34.5)	595	(31.5)	632	(33.9)	
-									

Table 1 Baseline characteristics of the women in the study population

¹Total annual income (wage, welfare payment and capital income) from the most recent Statistics Norway registration during 2014-2018, by tertiles of the total study population. Data missing for 37 women

Table 2 Screening participation among	long-term non-attenders by intervention arm.	and contrasts in any participation
		and contracto in any participation

	Control		Opt-in		Opt-out			Opt-in vs. Control		Opt-out vs. Control		Opt-out vs. Opt-in				
	N^1	Clinician sample n (%) ²	N^1	Self- sample n (%) ²	Clinician sample n (%) ²	Total n (%) ²	N^1	Self- sample n (%) ²	Clinician sample n (%) ²	Total n (%) ²	APD ³ (95% CI)	RP D ⁴ (95% Cl)	APD ³ (95% CI)	RPD^4 (95% CI)	APD ³ (95% CI)	RPD^4 (95% CI)
Total	1,892	90 (4.8)	1,897	250 (13.2)	73 (3.8)	323 (17.0)	1,878	445 (23.7)	75 (4.0)	520 (27.7)	12.3 (10.3, 14.2)	3.6 (2.9, 4.5)	22.9 (20.7, 25.2)	5.8 (4.7, 7.2)	10.7 (8.0, 13.3)	1.6 (1.4, 1.8)
Age group																
36 – 45	435	35 (8.0)	433	63 (14.5)	17 (3.9)	80 (18.5)	450	121 (26.9)	27 (6.0)	148 (32.9)	10.4 (6.0, 14.9)	2.3 (1.6, 3.3)	24.8 (19.8, 29.9)	4.1 (2.9, 5.8)	14.4 (8.7, 20.1)	1.8 (1.4, 2.3)
46 – 55	497	23 (4.6)	519	66 (12.7)	23 (4.4)	89 (17.1)	504	122 (24.2)	21 (4.2)	143 (28.4)	12.5 (8.8, 16.3)	3.7 (2.4, 5.8)	23.7 (19.4, 28.1)	6.1 (4.0, 9.4)	11.2 (6.1, 16.3)	1.7 (1.3, 2.1)
56 – 65	662	22 (3.3)	653	91 (13.9)	24 (3.7)	115 (17.6)	646	141 (21.8)	20 (3.1)	161 (24.9)	14.3 (11.1, 17.5)	5.3 (3.4, 8.3)	21.6 (18.0, 25.2)	7.5 (4.9, 11.6)	7.3 (2.9, 11.8)	1.4 (1.1, 1.8)
66 - 69	298	10 (3.4)	292	30 (10.3)	9 (3.1)	39 (13.4)	278	61(21.9)	7 (2.5)	68 (24.5)	10.0 (5.6, 14.4)	4.0 (2.0, 7.8)	21.1 (15.7, 26.6)	7.3 (3.8, 13.9)	11.1 (4.7, 17.5)	1.8 (1.3, 2.6)
Time since	last sci	reening tes	t													
10 - 15 yrs	598	52 (8.7)	589	101 (17.1)	34 (5.8)	135 (22.9)	599	165 (27.5)	29 (4.8)	194 (32.4)	14.2 (10.1, 18.3)	2.6 (2.0, 3.6)	23.7 (19.3, 28.1)	3.7 (2.8, 4.9)	9.5 (4.4, 14.5)	1.4 (1.2, 1.7)
16 - 28 yrs	650	26 (4.0)	658	92 (14.0)	22 (3.3)	114 (17.3)	642	152 (23.7)	15 (2.3)	167 (26.0)	13.3 (10.1, 16.6)	4.3 (2.9, 6.5)	22.0 (18.3, 25.7)	6.5 (4.4, 9,7)	8.7 (4.2, 13.1)	1.5 (1.2, 1.9)
Never	644	12 (1.9)	650	57 (8.8)	17 (2.6)	74 (11.4)	637	128 (20.1)	31 (4.9)	159 (25.0)	9.5 (6.9, 12.2)	6.1 (3.4, 11.1)	23.1 (19.6, 26.6)	13.4 (7.5, 23.8)	13.6 (9.4, 17.7)	2.2 (1.7, 2.8)

¹ Number of women invited

² Number (%) of women screened, among women invited

³Absolute participation difference, i.e. percentage point participation difference in screening by any mode (intention to treat)

⁴ Relative participation difference, i.e. relative risk of participation in screening by any mode (intention to treat)

Table 3 Proportion of hrHPV at screening¹ among long-term non-attenders in total and by intervention arm

All women screened by HPV-test				V-test	Control			Opt-in				Opt-out				
Type of HPV screening test	N	Any hr positive ² n(%)	16/18 positive ³ n(%)	Other hr positive ⁴ n(%)	N	Any hr positive ² n(%)	16/18 positive ³ n(%)	Other hr positive ⁴ n(%)	N	Any hr positive ² n(%)	16/18 positive ³ n(%)	Other hr positive ⁴ n(%)	N	Any hr positive ² n(%)	16/18 positive ³ n(%)	Other hr positive ⁴ n(%)
Total	913	100(11.0)	38(4.2)	60(6.6)	84	5(6.0)	0(0.0)	4(4.8)	314	34(10.8)	11(3.5)	23(7.3)	515	61(11.8)	27(5.3)	33(6.4)
Clin-sample	218	20(9.2)	5(2.3)	13(6.0)	84	5(6.0)	0(0.0)	4(4.8)	64	7(10.9)	2(3.1)	5(7.8)	70	8(11.4)	3(4.3)	4(5.7)
Self-sample	695	80(11.5)	33(4.8)	47(6.8)	-	-	-	-	250	27(10.8)	9(3.6)	18(7.2)	445	53(11.9)	24(5.4)	29(6.5)

¹ Women who attended clinician screening with cytology only (n=20) are not included. Six of these were in the control group, nine in the opt-in group and five in the opt-out group.

² Positive for one or more of the hrHPV-types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68. Two women (one control and 1 opt-out) were registered as any hrHPV positive, but lacked information on hrHPV-type

³ Positive for HPV16 and/or 18, and may be positive for other hrHPV-types

⁴ Positive for one or more of the hrHPV-types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68, but negative for 16/18

	Total, n (%)	Opt-in, n (%)	Opt-out, n (%)
Total			
Positive tests	80 (100.0)	27 (100.0)	53 (100.0)
Had triage test ²	63 (78.8)	21 (77.8)	42 (79.3)
Had triage test ³	74 (92.5)	25 (92.6)	49 (92.5)
Allocated gynaecologist			
Positive tests	41 (100.0)	12 (100.0)	29 (100.0)
Had triage test ²	31 (75.6)	10 (83.3)	21 (72.4)
Had triage test ³	37 (90.2)	11 (91.7)	26 (89.7)
Allocated RGP			
Positive tests	39 (100.0)	15 (100.0)	24 (100.0)
Had triage test ²	32 (82.1)	11 (73.3)	21 (87.5)
Had triage test ³	37 (94.9)	14 (93.3)	23 (95.8)

Table 4 Attendance to triage among long-term non-attenders with a hrHPV positive self-sample¹

¹Positive clinician-samples do not require attendance for triage and are hence not included in this table ² Attended follow-up within 6 months of notification of positive HPV-result, at allocated physician ³ Attended follow-up within 6 months of notification of positive HPV-result, regardless of where the exam took place

	Total, n (%)	Control, n(%)		Opt-in, n(%)			Opt-out, n(%)	
		Clinician-sample	Total	Self-sample	Clin-sample	Total	Self-sample	Clin-sample
Invited	5,667	1,892	1,897			1,878		
Screened	933 (16.4)	90 (4.8)	323 (17.0)	250 (13.2)	73 (3.8)	520 (27.7)	445 (23.7)	75 (4.0)
Had histology result ²	61 (1.1)	3 (0.2)	20 (1.1)	15 (0.8)	5 (0.3)	38 (2.0)	32 (1.7)	6 (0.3)
Had histology result ³	61 (6.5)	3 (3.3)	20 (8.6)	15 (6.0)	5 (6.8)	38 (7.3)	32 (7.2)	6 (8.0)
CIN2+ detected ²	33 (0.6)	1 (0.1)	12 (0.6)	9 (0.5)	3 (0.2)	20 (1.1)	17 (0.9)	3 (0.2)
CIN2+detected ³	33 (3.5)	1 (1.1)	12 (3.7)	9 (3.6)	3 (4.1)	20 (3.8)	17 (3.8)	3 (4.0)
CIN3+ detected ²	31 (0.5)	1 (0.1)	10 (0.5)	7 (0.4)	3 (0.2)	20 (1.1)	17 (0.9)	3 (0.2)
CIN3+ detected ³	31 (3.3)	1 (1.1)	10 (3.1)	7 (2.8)	3 (4.1)	20 (3.8)	17 (3.8)	3 (4.0)
Cervical cancer detected ³	11 (1.2)	0 (0.0)	4 (1.2)	3 (1.2)	1 (1.4)	7 (1.3)	6 (1.3)	1(1.3)

Table 5 Histologically verified high-grade lesions¹ among long-term non-attenders in total and by intervention arm

¹ CIN2, CIN3, ACIS or cancer ² Per cent of women invited ³ Per cent of women screened

	Women scr and triag	eened by self ged by gyneco	-sampling ologist ²	Women scr and	eened by self triaged by G	f-sampling P ³	Women screened by clinician (any arm) or triaged outside study ⁴					
	Total positive	16/18 positive⁵	Other HR positive ⁶	Total positive	16/18 positive⁵	Other HR positive ⁶	Total positive ⁷	16/18 positive⁵	Other H R positive ⁶	Cytology positive ⁸		
Total	31 (100.0)	14 (100.0)	17 (100.0)	32 (100.0)	9 (100.0)	23 (100.0)	34 (100.0)	13 (100.0)	17 (100.0)	2 (100.0)		
Had histology result ⁹	26 (83.9)	14 (100.0)	12 (70.6)	13 (40.6)	5 (55.6)	8 (34.8)	21 (61.8)	10 (76.9)	7 (41.2)	2 (100.0)		
CIN2+ detected ¹⁰	10 (32.3)	9 (64.3)	1 (5.9)	11 (34.4)	5 (55.6)	6 (26.1)	12 (35.3)	9 (69.2)	1(5.9)	2 (100.0)		
CIN3+ detected ¹¹	9 (29.0)	8 (57.1)	1 (5.9)	10 (31.3)	5 (55.6)	5 (21.7)	12 (35.3)	9 (69.2)	1(5.9)	2 (100.0)		
Cervical cancer detected	4 (12.9)	4 (28.6)	0 (0.0)	4 (12.5)	3 (33.3)	1 (4.3)	3 (8.8)	3 (23.1)	0 (0.0)	0 (0.0)		

Table 6 Histologically verified high-grade lesions (n, % of total) among screening test positive¹ women by triage mode

¹ Positive HPV test, or ASCUS+ for cytology
 ² Women from any self-sampling arm who were allocated to and attended gynecologist triage
 ³ Women from any self-sampling arm who were allocated to and attended GP triage

⁴ Women from any intervention arm who were screened by a clinician, and women from any self-sampling arm who self-sampled but were triaged outside the study ⁵ Positive for HPV16 and/or 18, and may be positive for other high-risk HPV types

⁶ Positive for any of the high-risk HPV-types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68, but not positive for 16/18 ⁷ Two women were registered as hr-HPV positive, but lacked information on hrHPV-type

⁸ Did not have HPV screening test

⁹ Registered with a histology diagnosis in the NCCSP/CRN databases

¹⁰ CIN2, CIN3, ACIS or cancer

¹¹ CIN3. ACIS or cancer



Fig 1. Study flowchart. Excluded women were either not reached, not eligible or declined to participate in the study



Fig. 2. Participation rate (%) during six months following the invitation